Search Tips
of 2 Next >
Results Found: 14
  • Liver Hepatocellular Carcinoma (TCGA, PanCancer Atlas)

    Description

    This dataset contains summary data visualizations and clinical data from a broad sampling of 372 liver hepatocellular carcinomas from 372 patients. The data was gathered as part of the PanCancer Atlas initiative, which aims to answer big, overarching questions about cancer by examining the full set of tumors characterized in the robust TCGA dataset. The clinical data includes mutation count, information...

    Subject
    Carcinoma, Hepatocellular
    DNA Mutational Analysis
    Access Rights
    Free to All
  • MSK-IMPACT Clinical Sequencing Cohort (MSKCC, Nat Med 2017): Targeted sequencing of 10,000 clinical cases using the MSK-IMPACT assay

    Description

    This dataset contains summary data visualizations and clinical data from the targeted sequencing of 10,000 clinical cases using the MSK-IMPACT assay. The clinical data includes mutation count, information about mutated genes, tumor mutational burden calculations, tissue site from which the sample was derived, tumor purity among other relevant data points. The data set also includes copy-number segment...

    Subject
    Adenocarcinoma
    Adenocarcinoma of Lung
    Adenocarcinoma, Mucinous
    Breast Neoplasms
    Carcinoma, Ductal, Breast
    Carcinoma, Hepatocellular
    Carcinoma, Lobular
    Carcinoma, Non-Small-Cell Lung
    Carcinoma, Renal Cell
    Carcinoma, Squamous Cell
    Carcinosarcoma
    Cholangiocarcinoma
    Colonic Neoplasms
    Colorectal Neoplasms
    Cystadenocarcinoma, Serous
    DNA Mutational Analysis
    Gallbladder Neoplasms
    Glioblastoma
    Liposarcoma
    Lung Neoplasms
    Lymphoma, Follicular
    Melanoma
    Mesothelioma
    Neoplasms, Squamous Cell
    Neurofibroma
    Oligodendroglioma
    Osteosarcoma
    Ovarian Neoplasms
    Pancreatic Neoplasms
    Prostatic Neoplasms
    Rectal Neoplasms
    Sarcoma
    Sarcoma, Synovial
    Squamous Cell Carcinoma of Head and Neck
    Stomach Neoplasms
    Thyroid Cancer, Papillary
    Urinary Bladder Neoplasms
    Uterine Neoplasms
    Uveal Neoplasms
    Access Rights
    Free to All
  • SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018): MSK-IMPACT sequencing of 86 patients with HER2- and HER3-mutant cancers

    Description

    This dataset contains summary data visualizations and clinical data from a broad sampling of HER2- and HER3-mutant tumors. The data was generated utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, Amplification Status, Best objective response rate, Bubble...

    Subject
    Breast Neoplasms
    Carcinoma, Hepatocellular
    Carcinoma, Non-Small-Cell Lung
    Carcinoma, Renal Cell
    Colorectal Neoplasms
    DNA Mutational Analysis
    Endometrial Neoplasms
    Esophageal Neoplasms
    Genes, erbB
    Genes, erbB-2
    Melanoma
    Ovarian Neoplasms
    Pancreatic Neoplasms
    Salivary Gland Neoplasms
    Sarcoma
    Skin Neoplasms
    Urinary Bladder Neoplasms
    Uterine Cervical Neoplasms
    Access Rights
    Free to All
  • Liver Hepatocellular Adenoma and Carcinomas (MSK, PLOS One 2018): Targeted sequencing of tumor/normal pairs of 9 LIAD and 10 HCC patients via MSK-IMPACT platform.

    Description

    This dataset contains summary data visualizations and clinical data from a broad sampling of hepatocellular adenomas and carcinomas. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), Patient ID, Sample ID, Cancer Type Detailed, Mutation Count, Fraction Genome Altered, Collaboration...

    Subject
    Adenoma, Liver Cell
    Carcinoma, Hepatocellular
    DNA Mutational Analysis
    Liver Neoplasms
    Access Rights
    Free to All
  • Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018): MSK-IMPACT sequencing of 127 Hepatocellular Carcinoma tumor samples with matched normals.

    Description

    This dataset contains summary data visualizations and clinical data from a broad sampling of hepatocellular carcinomas. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes mutation count, information about mutated genes, patient demographics, modality details, and disease status. The data set also includes copy-number segment data downloadable as .seg...

    Subject
    Carcinoma, Hepatocellular
    DNA Mutational Analysis
    Immunotherapy
    Liver Neoplasms
    Access Rights
    Free to All
  • Liver Hepatocellular Carcinoma

    Description

    TCGA Liver Hepatocellular Carcinoma. Source data from GDAC Firehose. Previously known as TCGA Provisional. This dataset contains summary data visualizations and clinical data from a broad sampling of 442 carcinomas from 440 patients. The data was gathered as part of the Broad Institute of MIT and Harvard Firehose initiative, a cancer analysis pipeline. The clinical data includes mutation count, information...

    Subject
    Carcinoma, Hepatocellular
    DNA Mutational Analysis
    Liver Neoplasms
    Access Rights
    Free to All
  • Proteomics Data for "PD-1-targeted immunotherapy in NASH-triggered liver cancer induces pro-tumorigenic environment through CD8+PD-1+ T-cells"

    Authors
    Oroshi, Mario
    Meissner, Felix
    Description

    Investigating the NASH-triggered HCC in the context PD-1-targeted immunotherapy with flow cytometry, single cell RNA sequencing, immunohistochemistry and mass spectrometric analyses, we found a progressive increase of CD8+PD-1+ effector T-cells with a unique profile of exhaustion and activation markers rising with murine and human NASH severity. Notably, late-stage HCC treatment with PD-1-targeted...

    Subject
    Carcinoma, Hepatocellular
    CD8-Positive T-Lymphocytes
    Immune Checkpoint Inhibitors
    Non-alcoholic Fatty Liver Disease
    Access Rights
    Free to All
  • PD-1-targeted immunotherapy in NASH-triggered liver cancer induces pro-tumorigenic environment through CD8+PD-1+ T-cells

    Authors
    Pfister, Dominik
    Núñez, Nicolás Gonzalo
    Govaere, Olivier
    Sinha, Ankit
    6 more author(s)...
    Description

    Summary from the GEO: "Whereas some cancer types (e.g. melanoma) can be efficiently treated with immunotherapy, others lack measurable positive effects (e.g. PDAC ). Moreover, stratification of responders/non-responders is only possible in some cancer types (e.g. melanoma). Hepatocellular carcinoma (HCC) has a dismal prognosis, limited treatment options and survival benefit, and represents a potential...

    Subject
    Carcinoma, Hepatocellular
    CD8-Positive T-Lymphocytes
    Immune Checkpoint Inhibitors
    Non-alcoholic Fatty Liver Disease
    Access Rights
    Free to All
  • Immune-checkpoint blockade lacks anti-tumorgenicity in NASH-induced HCC

    Authors
    Pfister, Dominik
    Núñez, Nicolás Gonzalo
    Pinyol, Roser
    Govaere, Olivier
    104 more author(s)...
    Description

    Summary from the GEO: "Hepatocellular carcinoma (HCC) has dismal treatment responses to systemic therapies and is caused by both, viral and non-viral etiologies, including non-alcoholic steatohepatitis (NASH) 1–5. NASH - triggered by high caloric intake and sedentary lifestyle - has become an important driver for HCC development. Immunotherapy has been recently approved for HCC but stratification...

    Subject
    Carcinoma, Hepatocellular
    CD8-Positive T-Lymphocytes
    Immune Checkpoint Inhibitors
    Non-alcoholic Fatty Liver Disease
    Access Rights
    Free to All
  • PD-1-targeted immunotherapy in non-alcoholic steatohepatitis-induced liver cancer induces a pro-tumorigenic environment through CD8+ PD1+ T-cells.​​

    Description

    Summary from the ENA: "Mice with advanced non alcoholic fatty liver disease (NASH) by dietary feeding regime of choline deficient high fat diet (CD-HFD) were treated with antibodies (a-CD8 depletion; a-PD1 checkpoint inhibition; Co-depletion by a-CD8 and a-NK1.1 administration) for 8 weeks. Surprisingly, a-CD8 depletion prevented hepatocarcinogenesis; in contrast a-PD1 checkpoint inhibition induced...

    Subject
    Carcinoma, Hepatocellular
    CD8-Positive T-Lymphocytes
    Immune Checkpoint Inhibitors
    Non-alcoholic Fatty Liver Disease
    Access Rights
    Free to All